Floatz logo

Aldafermin

Metabolic Dysfunction-Associated Steatohepatitis

NGM Biopharmaceuticals, Incprotein_peptidePhase 2Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

128 Active assets in the Metabolic Dysfunction-Associated Steatohepatitis cohort.

Asset / SponsorPhaseRating
Resmetirom
City University of New York
Phase 4BBB
Pentoxifylline
Al-Azhar University
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB
Firsocostat
Gilead Sciences
Phase 2BBB
Montelukast
Tanta University
Phase 4BBB

View all 50 →

Same molecule, other indications

Aldafermin is also rated in:

primary sclerosing cholangitisActive
B
Indicative · Phase 2/3
62 / 100
View asset →
primary biliary cholangitisDormant
B
Indicative · Phase 2
62 / 100
View asset →
cirrhosis of liverDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →